ÈËÆÞÖгöÊÓƵ

Monika Fleckenstein
( out of 232 reviews )

Monika Fleckenstein, MD

Languages spoken: English

Clinical Locations

Midvalley ÈËÆÞÖгöÊÓƵ Center

Murray
801-581-2955

  • Monika Fleckenstein, MD, specializes in the management and medical treatment of retinal diseases, with a special emphasis on age-related macular degeneration (AMD).

    Learn more about Dr. Fleckenstein's clinical practice .

    Dr. Fleckenstein joined the John A. Moran Eye Center in 2019 as a Professor of Ophthalmology and Visual Sciences, with clinical and research appointments. After earning her medical degree at the ÈËÆÞÖгöÊÓƵ of Heidelberg, Germany, Dr. Fleckenstein honed her skills as a research fellow at the Wilmer Eye Institute at Johns Hopkins ÈËÆÞÖгöÊÓƵ and later completed her ophthalmology residency at the ÈËÆÞÖгöÊÓƵ of Bonn, Germany.

    Research

    Dr. Fleckenstein's primary research interest centers around degenerative retinal diseases, with a focus on AMD. She specializes in applying advanced high-resolution imaging technology to characterize AMD subtypes, identifying prognostic biomarkers for disease progression, and validating clinical endpoints for interventional trials. These efforts have yielded a substantial body of work, including over 100 peer-reviewed publications and 25 book chapters.

    In addition to her research contributions, Dr. Fleckenstein plays a vital role as a scientific reviewer for esteemed ophthalmology journals and serves on grant review committees for prestigious organizations such as the National Institutes of ÈËÆÞÖгöÊÓƵ (NIH) and the German Research Foundation.

    Dr. Fleckenstein served as the head of the ÈËÆÞÖгöÊÓƵ of Bonn Department of Ophthalmology Clinical Trial Center from 2013 to 2019. At present, Dr. Fleckenstein is actively contributing her expertise to translational research initiatives at the Moran Eye Center's . She serves as the principal investigator/multi-principal investigator for two separate NIH grants, each dedicated to clinically characterizing distinct AMD subtypes: "The Impact of Non-Exudative Type 1 Macular Neovascularization on AMD Progression" (R01EY033365) and "Progression of Early Atrophic Lesions in AMD" (R01EY034965).

    Specialties

    Board Certification

    Medical Association of North Rhine-Ophthalmology

    Patient Rating

    4.9 /5
    ( out of 232 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 30, 2024
    MORAN EYE CENTER

    Dr Fleckenstein was respectful, listened well and answered well-I felt see viewed me very individually-Many practices use a one size fits all approach whereas Dr. Fleckenstein didn't try to fit me into a specific box (a certain protocol the steps of which other practices follow)

    October 29, 2024
    MORAN EYE CENTER

    She is a kind person.

    October 19, 2024
    MORAN EYE CENTER

    She takes time to explain, especially to reiterate things to NOT be worried about.

    October 19, 2024
    MORAN EYE CENTER

    She is the best! So upbeat every time.

    October 18, 2024
    MORAN EYE CENTER

    Trust, respect, affection and a measure of humor thrown in comes to mind.

    October 17, 2024
    MORAN EYE CENTER

    Excellent. One of the best doctors I have ever encountered.

    October 12, 2024
    MORAN EYE CENTER

    Dr. Fleckenstein simply the best. Always begins by asking how my eyes are doing and seeking input about any detail. Her treatment approach is very professional and gives me great confidence. I'll be her patient flor the long term with confidence.

    October 07, 2024
    MORAN EYE CENTER

    She was kind and answered questions. She was very careful not to hurt me.

    October 04, 2024
    MORAN EYE CENTER

    She is very business in her approach. Explaines what is happening and is quick with procedure which b Is great.

    See More Patient Comments

  • Monika Fleckenstein, MD, specializes in the management and medical treatment of retinal diseases, with a special emphasis on age-related macular degeneration (AMD).

    Learn more about Dr. Fleckenstein's clinical practice .

    Dr. Fleckenstein joined the John A. Moran Eye Center in 2019 as a Professor of Ophthalmology and Visual Sciences, with clinical and research appointments. After earning her medical degree at the ÈËÆÞÖгöÊÓƵ of Heidelberg, Germany, Dr. Fleckenstein honed her skills as a research fellow at the Wilmer Eye Institute at Johns Hopkins ÈËÆÞÖгöÊÓƵ and later completed her ophthalmology residency at the ÈËÆÞÖгöÊÓƵ of Bonn, Germany.

    Research

    Dr. Fleckenstein's primary research interest centers around degenerative retinal diseases, with a focus on AMD. She specializes in applying advanced high-resolution imaging technology to characterize AMD subtypes, identifying prognostic biomarkers for disease progression, and validating clinical endpoints for interventional trials. These efforts have yielded a substantial body of work, including over 100 peer-reviewed publications and 25 book chapters.

    In addition to her research contributions, Dr. Fleckenstein plays a vital role as a scientific reviewer for esteemed ophthalmology journals and serves on grant review committees for prestigious organizations such as the National Institutes of ÈËÆÞÖгöÊÓƵ (NIH) and the German Research Foundation.

    Dr. Fleckenstein served as the head of the ÈËÆÞÖгöÊÓƵ of Bonn Department of Ophthalmology Clinical Trial Center from 2013 to 2019. At present, Dr. Fleckenstein is actively contributing her expertise to translational research initiatives at the Moran Eye Center's . She serves as the principal investigator/multi-principal investigator for two separate NIH grants, each dedicated to clinically characterizing distinct AMD subtypes: "The Impact of Non-Exudative Type 1 Macular Neovascularization on AMD Progression" (R01EY033365) and "Progression of Early Atrophic Lesions in AMD" (R01EY034965).

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    Medical Association of North Rhine-Ophthalmology

    Education history

    Professional Medical Ophthalmology - ÈËÆÞÖгöÊÓƵ of Bonn Dr. med. habil
    Inherited Retinal Diseases - Johns Hopkins ÈËÆÞÖгöÊÓƵ Research Fellow
    Doctoral Training Experimental Anesthesiology - ÈËÆÞÖгöÊÓƵ of Freiburg Dr. med.
    Medicine - ÈËÆÞÖгöÊÓƵ of Heidelberg School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Pfau M, Schmitz-Valckenberg S, Ribeiro R, Safaei R, McKeown A, Fleckenstein M, Holz FG (2022). Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep, 12(1), 17870. ()
    2. Schmitz-Valckenberg S, Fleckenstein M, Zouache MA, Pfau M, Pappas C, Hageman JL, Agrn E, Malley C, Keenan TDL, Chew EY, Hageman GS (2022). Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both. JAMA Ophthalmol, 140(3), 252-260. ()
    3. Knzel SH, Lindner M, Sassen J, Mller PT, Goerdt L, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2021). Association of Reading Performance in Geographic Atrophy Secondary to Age-Related Macular Degeneration With Visual Function and Structural Biomarkers. JAMA Ophthalmol, 139(11), 1191-1199. ()
    4. Pfau M, van Dijk EHC, van Rijssen TJ, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Boon CJF (2021). Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. Sci Rep, 11(1), 20446. ()
    5. Behning C, Fleckenstein M, Pfau M, Adrion C, Goerdt L, Lindner M, Schmitz-Valckenberg S, Holz FG, Schmid M (2021). Modeling of atrophy size trajectories: variable transformation, prediction and age-of-onset estimation. BMC Med Res Methodol, 21(1), 170. ()
    6. Goerdt L, Sauer L, Vitale AS, Modersitzki NK, Fleckenstein M, Bernstein PS (2021). Comparing Fluorescence Lifetime Imaging Ophthalmoscopy in Atrophic Areas of Retinal Diseases. Transl Vis Sci Technol, 10(7), 11. ()
    7. Pfau M, Sahu S, Rupnow RA, Romond K, Millet D, Holz FG, Schmitz-Valckenberg S, Fleckenstein M, Lim JI, de Sisternes L, Leng T, Rubin DL, Hallak JA (2021). Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. Transl Vis Sci Technol, 10(7), 30. ()
    8. Mller PL, Pfau M, Schmitz-Valckenberg S, Fleckenstein M, Holz FG (2020). Optical Coherence Tomography-Angiography in Geographic Atrophy. Ophthalmologica, 244(1), 42-50. ()
    9. Huss MB, Schmitz-Valckenberg S, Finger RP, Lffler KU, Fleckenstein M, Holz FG, Pfau M (2020). The Willingness of Patients to Participate in an Eye Donation Registry for Research. Ophthalmologica, 244(3), 179-186. ()
    10. Pfau M, Jolly JK, Wu Z, Denniss J, Lad EM, Guymer RH, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. Prog Retin Eye Res, 82, 100907. ()
    11. Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Rubin DL (2021). Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmol, 138(10), 1026-1034. ()
    12. Pfau M, Walther G, von der Emde L, Berens P, Faes L, Fleckenstein M, Heeren TFC, Kortm K, Knzel SH, Mller PL, Maloca PM, Waldstein SM, Wintergerst MWM, Schmitz-Valckenberg S, Finger RP, Holz FG (2020). [Artificial intelligence in ophthalmology : Guidelines for physicians for the critical evaluation of studies]. Ophthalmologe, 117(10), 973-988. ()
    13. Pfau M, von der Emde L, Dysli C, Mller PT, Thiele S, Lindner M, Schmid M, Rubin DL, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Determinants of Cone and Rod Functions in Geographic Atrophy: AI-Based Structure-Function Correlation. Am J Ophthalmol, 217, 162-173. ()
    14. Schmitz-Valckenberg S, Pfau M, Fleckenstein M, Staurenghi G, Sparrow JR, Bindewald-Wittich A, Spaide RF, Wolf S, Sadda SR, Holz FG (2020). Fundus autofluorescence imaging. Prog Retin Eye Res, 81, 100893. ()
    15. Sassmannshausen M, Pfau M, Thiele S, Fimmers R, Steinberg JS, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(10), 19. ()
    16. Samannshausen M, Zhou J, Pfau M, Thiele S, Steinberg J, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Retinal Thickness and Retinal Function in Eyes with Large Drusen Secondary to Intermediate Age-Related Macular Degeneration. Ophthalmol Retina, 5(3), 241-250. ()
    17. Dieck S, Ibarra M, Moghul I, Yeung MW, Pantel JT, Thiele S, Pfau M, Fleckenstein M, Pontikos N, Krawitz PM (2020). Factors in Color Fundus Photographs That Can Be Used by Humans to Determine Sex of Individuals. Transl Vis Sci Technol, 9(7), 8. ()
    18. Knzel SH, Mller PT, Lindner M, Goerdt L, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2020). Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(5), 63. ()
    19. Thiele S, Nadal J, Pfau M, Samannshausen M, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S (2020). Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression. Br J Ophthalmol. ()
    20. Eter N, Pauleikhoff D, Agostini H, Fleckenstein M, Ziemssen F (2020). [Value and formats of quality assurance : Ophthalmology and intravitreal therapy between reality and wishful thinking]. Ophthalmologe, 117(4), 298-306. ()
    21. Guymer RH, Rosenfeld PJ, Curcio CA, Holz FG, Staurenghi G, Freund KB, Schmitz-Valckenberg S, Sparrow J, Spaide RF, Tufail A, Chakravarthy U, Jaffe GJ, Csaky K, Sarraf D, Mons JM, Tadayoni R, Grunwald J, Bottoni F, Liakopoulos S, Pauleikhoff D, Pagliarini S, Chew EY, Viola F, Fleckenstein M, Blodi BA, Lim TH, Chong V, Lutty J, Bird AC, Sadda SR (2019). Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology, 127(3), 394-409. ()
    22. Pfau M, Mller PT, Knzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina, 4(3), 238-248. ()
    23. Thiele S, Nadal J, Pfau M, Samannshausen M, von der Emde L, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S, Molecular Diagnostic of Age-related Macular Degeneration Study Group (2019). Prognostic Value of Retinal Layers in Comparison with Other Risk Factors for Conversion of Intermediate Age-related Macular Degeneration. Ophthalmol Retina, 4(1), 31-40. ()
    24. von der Emde L, Thiele S, Pfau M, Nadal J, Meyer J, Mller PT, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography. Ophthalmologica, 243(2), 120-128. ()
    25. Pfau M, von der Emde L, Dysli C, Thiele S, Mller PT, Lindner M, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Light Sensitivity Within Areas of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 60(12), 3992-4001. ()
    26. Bhringer D, Goos D, Ach T, Feltgen N, Fleckenstein M, Kohnen T, Lorenz K, Pielen A, Spital G, Wilhelm B, Bhringer S, Reinhard T, Arbeitsgemeinschaft DOG Klinische Studienzentren (2019). [Work sampling in ophthalmological clinical studies. A multicenter field study]. Ophthalmologe, 116(9), 872-878. ()
    27. Fleckenstein M, Thiele S, Pfau M, Schmitz-Valckenberg S, Holz FG (2019). [Dry Age-Related Macular Degeneration - Epidemiology and Classification]. Klin Monbl Augenheilkd, 236(9), 1068-1075. ()
    28. Bax NM, Valkenburg D, Lambertus S, Klevering BJ, Boon CJF, Holz FG, Cremers FPM, Fleckenstein M, Hoyng CB, Lindner M, Foveal Sparing Atrophy Study Team FAST (2019). Foveal Sparing in Central Retinal Dystrophies. Invest Ophthalmol Vis Sci, 60(10), 3456-3467. ()
    29. Pfau M, Lindner M, Goerdt L, Thiele S, Nadal J, Schmid M, Schmitz-Valckenberg S, Sadda SR, Holz FG, Fleckenstein M, Fundus Autofluorescence in Age-Related Macular Degeneration Study Group (2018). PROGNOSTIC VALUE OF SHAPE-DESCRIPTIVE FACTORS FOR THE PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 39(8), 1527-1540. ()
    30. von der Emde L, Pfau M, Dysli C, Thiele S, Mller PT, Lindner M, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. Sci Rep, 9(1), 11132. ()
    31. Grassmann F, Harsch S, Brandl C, Kiel C, Nrnberg P, Toliat MR, Fleckenstein M, Pfau M, Schmitz-Valckenberg S, Holz FG, Chew EY, Swaroop A, Ratnapriya R, Klein ML, Mulyukov Z, Zamiri P, Weber BHF (2019). Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration. JAMA Ophthalmol. ()
    32. Lindner M, Pfau M, Czauderna J, Goerdt L, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Determinants of Reading Performance in Eyes with Foveal-Sparing Geographic Atrophy. Ophthalmol Retina, 3(3), 201-210. ()
    33. Birtel J, Lindner M, Mishra DK, Mller PL, Hendig D, Herrmann P, Holz FG, Fleckenstein M, Gliem M, Charbel Issa P (2018). Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. Clin Exp Ophthalmol, 47(2), 240-249. ()
    34. Pfau M, Lindner M, Gliem M, Steinberg JS, Thiele S, Finger RP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and dark-adapted two-color fundus-controlled perimetry in patients with cuticular, reticular, and soft drusen. Eye (Lond), 32(12), 1819-1830. ()
    35. Pfau M, Lindner M, Steinberg JS, Thiele S, Brinkmann CK, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Visual field indices and patterns of visual field deficits in mesopic and dark-adapted two-colour fundus-controlled perimetry in macular diseases. Br J Ophthalmol, 102(8), 1054-1059. ()
    36. Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Mons JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G (2017). Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology, 125(4), 537-548. ()
    37. Mller PL, Pfau M, Mller PT, Nadal J, Schmid M, Lindner M, de Sisternes L, Sthr H, Weber BHF, Neuhaus C, Herrmann P, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related Macular Degeneration: An OCT-Angiography Study. Invest Ophthalmol Vis Sci, 59(4), AMD122-AMD131. ()
    38. Lindner M, Kosanetzky S, Pfau M, Nadal J, Gordt LA, Schmitz-Valckenberg S, Schmid M, Holz FG, Fleckenstein M (2018). Local Progression Kinetics of Geographic Atrophy in Age-Related Macular Degeneration Are Associated With Atrophy Border Morphology. Invest Ophthalmol Vis Sci, 59(4), AMD12-AMD18. ()
    39. Thiele S, Pfau M, Larsen PP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(4), AMD1-AMD11. ()
    40. Sassmannshausen M, Steinberg JS, Fimmers R, Pfau M, Thiele S, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Structure-Function Analysis in Patients With Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(3), 1599-1608. ()
    41. von der Emde L, Pfau M, Thiele S, Mller PT, Hassenrik R, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Transl Vis Sci Technol, 8(1), 7. ()
    42. Thiele S, Nadal J, Fleckenstein M, Fang PP, Pfau M, Schmid M, Hua R, Holz FG, Schmitz-Valckenberg S (2018). Longitudinal Analysis of Drusen Volume in Intermediate Age-Related Macular Degeneration Using Two Spectral-Domain Optical Coherence Tomography Scan Patterns. Ophthalmologica, 239(2-3), 110-120. ()
    43. Steinberg JS, Samannshausen M, Pfau M, Fleckenstein M, Finger RP, Holz FG, Schmitz-Valckenberg S (2017). Evaluation of Two Systems for Fundus-Controlled Scotopic and Mesopic Perimetry in Eye with Age-Related Macular Degeneration. Transl Vis Sci Technol, 6(4), 7. ()
    44. Oishi M, Oishi A, Lindner M, Pfau M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2017). Structural Changes in Optical Coherence Tomography Underlying Spots of Increased Autofluorescence in the Perilesional Zone of Geographic Atrophy. Invest Ophthalmol Vis Sci, 58(7), 3303-3310. ()
    45. Pfau M, Lindner M, Muller PL, Birtel J, Finger RP, Harmening WM, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2017). Effective Dynamic Range and Retest Reliability of Dark-Adapted Two-Color Fundus-Controlled Perimetry in Patients With Macular Diseases. Invest Ophthalmol Vis Sci, 58(6), BIO158-BIO167. ()
    46. Pfau M, Goerdt L, Schmitz-Valckenberg S, Mauschitz MM, Mishra DK, Holz FG, Lindner M, Fleckenstein M (2017). Green-Light Autofluorescence Versus Combined Blue-Light Autofluorescence and Near-Infrared Reflectance Imaging in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 58(6), BIO121-BIO130. ()
    47. Lindner M, Nadal J, Mauschitz MM, Luning A, Czauderna J, Pfau M, Schmitz-Valckenberg S, Holz FG, Schmid M, Fleckenstein M (2017). Combined Fundus Autofluorescence and Near Infrared Reflectance as Prognostic Biomarkers for Visual Acuity in Foveal-Sparing Geographic Atrophy. Invest Ophthalmol Vis Sci, 58(6), BIO61-BIO67. ()
    48. Ribeiro L, Bandello F, Tejerina AN, Vujosevic S, Varano M, Egan C, Sivaprasad S, Menon G, Massin P, Verbraak FD, Lund-Andersen H, Martinez JP, Jrgens I, Smets E, Coriat C, Wiedemann P, goas V, Querques G, Holz FG, Nunes S, Neves C, Cunha-Vaz J, Evicr Net Study Group (2015). Collaborator: Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2.  . Invest Ophthalmol Vis Sci, 56(9), 5698-705. ()

    Review

    1. von der Emde L, Pfau M, Holz FG, Fleckenstein M, Kortuem K, Keane PA, Rubin DL, Schmitz-Valckenberg S (2021). AI-based structure-function correlation in age-related macular degeneration. [Review]. Eye (Lond), 35(8), 2110-2118. ()
    2. Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY (2021). Age-related macular degeneration. [Review]. Nat Rev Dis Primers, 7(1), 31. ()
    3. Pfau M, Jolly JK, Wu Z, Denniss J, Lad EM, Guymer RH, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. [Review]. Prog Retin Eye Res, 82, 100907. ()
    4. Schmitz-Valckenberg S, Pfau M, Fleckenstein M, Staurenghi G, Sparrow JR, Bindewald-Wittich A, Spaide RF, Wolf S, Sadda SR, Holz FG (2020). Fundus autofluorescence imaging. [Review]. Prog Retin Eye Res, 81, 100893. ()
    5. Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, Henry EC, Ferrara D (2018). The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. [Review]. Ophthalmology, 125(3), 369-390. ()

    Conference Proceedings

    1. Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Mons JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G (2018). Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology, United States, 125(4), 537-548. ()
    2. Holz FG, Sadda SR, Staurenghi G, Lindner M, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Curcio CA, Danis R, Fleckenstein M, Freund KB, Grunwald J, Guymer R, Hoyng CB, Jaffe GJ, Liakopoulos S, Mones JM, Oishi A, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Schmitz-Valckenberg S (2017). Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. Ophthalmology, United States, 124(4), 464-478. ()

  • News & Podcasts

    Podcasts